Phaseline

Targets › PNPO

PNPO (Pyridoxine-5'-phosphate oxidase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Metabolic and endocrine; next expected readout Sep 2027.

Catalyzes the oxidation of either pyridoxine 5'-phosphate (PNP) or pyridoxamine 5'-phosphate (PMP) into pyridoxal 5'-phosphate (PLP). (UniProt, Q9NVS9)

Open in Phaseline: the race on PNPO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
MedicurePyridoxal Phosphate
Pyridoxal 5'-phosphate (active form of vitamin B6) cofactor replacement for PNPO deficienc
PNPOPhase 3Pyridox(am)Ine 5'-Phosphate Oxidase DeficiencySep 2027

Conditions

Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency (1)

Modalities

small molecule (1)

Companies

Medicure (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.